PT -期刊文章盟保罗Preziosa AU -朱塞佩·A·拉米雷斯盟艾瑞卡Bozzolo Patrizia Rovere-Querini盟盟- -安吉洛曼AU -马西莫菲利皮主持AU -玛丽亚·A·罗卡TI -受损的大脑结构连接体在系统性红斑狼疮和多发性硬化症患者:图论研究(P1.393) DP - 2018年4月10 TA -神经病学PG - P1.393 VI - 90 IP - 15补充4099 - //www.ez-admanager.com/content/90/15_Supplement/P1.393.short 4100 - //www.ez-admanager.com/content/90/15_Supplement/P1.393.full所以Neurol首页ogy2018 4月10;90 AB -目的:探索大脑结构连接体的地形组织系统性红斑狼疮(SLE)患者与健康对照组比较(HC)和复发缓和多发性硬化(名RRMS)患者。背景:焦点在常规MRI大脑异常,普遍异常正常白质和灰质和功能性皮质的变化描述系统性红斑狼疮患者有或没有临床证据的神经(NP)的参与。设计/方法:大脑dual-echo, 3 d t1和扩散张量(DT)来自32个系统性红斑狼疮患者的MRI扫描与NP-SLE(12), 32名RRMS患者和32 HC,匹配对年龄、性别和疾病持续时间(病人)。116皮层和皮层下脑区之间的结构连接矩阵估计,全球和节点网络指标计算。Results: Compared to HC, both SLE and MS patients showed decreased (p<0.0001) strength, transitivity, global efficiency and increased average path length of the whole network. These abnormalities were less severe in SLE than in MS patients (p from 0.005 to 0.01). Similar hubs were identified in all three groups. In SLE and MS patients, all hubs showed a reduced strength compared to HC (p from <0.0001 to 0.001). Compared to SLE, MS patients showed lower strength in hubs located in fronto-temporo-parieto-occipital cortices, subcortical nuclei (including the thalamus, caudate nucleus and putamen) and cerebellum (p from 0.001 to 0.05). No significant differences in global and regional measures was found comparing SLE patients with and without neuropsychiatric involvement.Conclusions: Significant abnormalities of global and regional structural connectivity measures occur both in SLE and MS patients, suggesting a diffuse disruption of structural integrity. The extent of such abnormalities is more severe in MS than in SLE patients.Disclosure: Dr. Preziosa has nothing to disclose. Dr. Ramirez has nothing to disclose. Dr. Bozzolo has nothing to disclose. Dr. Rovere-Querini has nothing to disclose. Dr. Manfredi has nothing to disclose. Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Novartis, Teva Pharmaceutical Industries. Dr. Rocca has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva Neurosciences and Genzyme.